The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $3.51 in the prior trading day, Summit Therapeutics Inc (NASDAQ: SMMT) closed at $3.50, down -0.28%. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 1.73 million shares were traded. SMMT stock price reached its highest trading level at $3.55 during the session, while it also had its lowest trading level at $3.34.
Ratios:
Our goal is to gain a better understanding of SMMT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.30 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 26, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 ’24 when Zanganeh Mahkam bought 54,321 shares for $3.72 per share. The transaction valued at 201,874 led to the insider holds 24,923,800 shares of the business.
Zanganeh Mahkam bought 26,000 shares of SMMT for $96,720 on Mar 27 ’24. The Chief Executive Officer now owns 520,814 shares after completing the transaction at $3.72 per share. On Mar 26 ’24, another insider, Dhingra Ankur, who serves as the Chief Financial Officer of the company, bought 100,000 shares for $3.75 each. As a result, the insider paid 375,000 and bolstered with 354,958 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 2455960320 and an Enterprise Value of 2375797248.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $5.22, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is -15.97%, while the 200-Day Moving Average is calculated to be 28.93%.
Shares Statistics:
The stock has traded on average 2.30M shares per day over the past 3-months and 1563760 shares per day over the last 10 days, according to various share statistics. A total of 701.66M shares are outstanding, with a floating share count of 82.98M. Insiders hold about 88.17% of the company’s shares, while institutions hold 4.64% stake in the company. Shares short for SMMT as of 1711584000 were 21805380 with a Short Ratio of 9.47, compared to 1709164800 on 15951064. Therefore, it implies a Short% of Shares Outstanding of 21805380 and a Short% of Float of 26.19.
Earnings Estimates
A comprehensive evaluation of Summit Therapeutics Inc (SMMT) is underway, with the input of SMOT analysts contributing to its current rating.The consensus estimate for the next quarter is $3.50, with high estimates of $27.20 and low estimates of $2.29.
